Pricing

Immatics N.V. (IMTX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Harpreet Singh-Jasuja
Employees:
260
PAUL EHRLICH-STRASSE 15, TUBINGEN, 2M, 72076
49 7071 5397 700

Are you looking for this stock instead?

Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available